NR3C2 and obesity disorder: Pharmacotherapies targeting RAAS, including ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists (MRAs) or renin inhibitors, may decrease high BP among patients with obesity [12, 13].